Geographic atrophy due to AMD, in which an overactivity of the complement system destroys cells in the macula, the central part of the retina responsible for central vision, can lead to blindness. HMR59 is designed to increase the ability of retina cells in the eye to make a soluble form of CD59 (low in AMD patients), helping to prevent further damage to the retina and preserve vision.

A phase I study of HMR59 in patients with geographic atrophy has already been completed. An ongoing phase I study in patients with wet-AMD is evaluating the long-term safety of HMR59.

Financial terms of the deal were not disclosed.

Diamond Pharma, GenSight submit EMA application for ocular gene therapy
French biotechnology firm GenSight Biologics has submitted a marketing authorization application to the European Medicines Agency (EMA) for its ocular...

Customized gene therapies successfully target rare eye diseases
Can gene therapies prove effective for the treatment of rare genetic diseases? One company may have found a solution that incorporates a high degree of...